Literature DB >> 26748580

Editorial: Biosimilars: New or Déjà Vu?

Jonathan Kay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26748580     DOI： 10.1002/art.39568

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  3 in total

1.  Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.

Authors:  Josef S Smolen; Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieskawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Jasmine Choi; Young Hee Rho
Journal:  Rheumatology (Oxford)       Date:  2017-10-01       Impact factor: 7.580

2.  Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.

Authors:  Josef S Smolen; Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieslawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Younju Lee; Young Hee Rho
Journal:  Ann Rheum Dis       Date:  2017-10-17       Impact factor: 19.103

3.  Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.

Authors:  S Gerdes; D Thaçi; C E M Griffiths; P Arenberger; J Poetzl; G Wuerth; M Afonso; H Woehling
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-02       Impact factor: 6.166
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.